FDA Approves First mRNA Flu Vaccine for Adults 50 and Older

The FDA approved Moderna's mFLUSIVA on August 5, 2026, the first mRNA flu vaccine for adults 50+. The technology allows faster manufacturing and strain matching compared to traditional egg-based flu shots.

mRNA vaccine technology and advantages

• ▪Most vaccinologists believe mRNA vaccines are the future of flu prevention
• ▪mRNA technology allows faster manufacturing and quicker response to circulating flu strains than traditional egg-based production

Debatable claims

• ▪The FDA's dispute with Moderna over trial data delayed approval of a needed vaccine
• ▪mRNA flu vaccines will prove more effective than traditional flu shots at preventing seasonal influenza

FDA approval and regulatory process

• ▪The vaccine is approved for adults 50 and older, the age group that accounts for most flu deaths
• ▪FDA approved Moderna's mFLUSIVA on August 5, 2026, the first mRNA-based seasonal influenza vaccine
• ▪The approval followed a dispute between Moderna and the FDA over trial data requirements